nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.03.2014 | Review Paper

The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms

verfasst von: Yue Teng, Xu Li

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Epithelial-to-mesenchymal transition (EMT) is presently recognized as an important event and the initiating stage for tumor invasion and metastasis. Several EMT inducers have been identified, among which the big family of helix–loop–helix (HLH) transcription factors are rising as a novel and promising family of proteins in EMT mediation, such as Twist1, Twist2, E47, and HIFs, etc. Due to the variety and complexities of HLH members, the pathways and mechanisms they employ to promote EMT are also complex and characteristic. In this review, we will discuss the roles of various HLH proteins in the regulation and sustenance of the EMT and multiple cellular mechanisms, attempting to provide a novel and broadened view towards the link between HLH proteins and EMT.

Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial–mesenchymal transitions in development and disease. Cell 139:871–890PubMed

De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13(2):97–110PubMed

Lamouille S, Subramanyam D, Blelloch R, Derynck R (2013) Regulation of epithelial–mesenchymal and mesenchymal–epithelial transitions by microRNAs. Curr Opin Cell Biol 25:200–207PubMed

Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198(1):11–26PubMed

Zheng H, Kang Y (2013) Multilayer control of the EMT master regulators. Oncogene. doi:10.1038/onc.2013.128 PubMedCentral

May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA (2011) Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 13(1):202PubMedCentralPubMed

Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265–273PubMed

Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415–428PubMed

Long CL, Berry WL, Zhao Y, Sun XH, Humphrey MB (2012) E proteins regulate osteoclast maturation and survival. J one Miner Res 27(12):2476–2489

10.

Havis E, Coumailleau P, Bonnet A, Bismuth K, Bonnin MA, Johnson R, Fan CM, Relaix F, Shi DL, Duprez D (2012) Sim2 prevents entry into the myogenic program by repressing MyoD transcription during limb embryonic myogenesis. Development 139(11):1910–1920PubMed

11.

Farah MH, Olson JM, Sucic HB, Hume RI, Tapscott SJ, Turner DL (2000) Generation of neurons by transient expression of neural bHLH proteins in mammalian cells. Development 127(4):693–702PubMed

12.

Norton JD (2000) ID helix–loop–helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 113(22):3897–3905PubMed

13.

Fritzsch B, Eberl DF, Beisel KW (2010) The role of bHLH genes in ear development and evolution: revisiting a 10-year-old hypothesis. Cell Mol Life Sci 67(18):3089–3099PubMedCentralPubMed

14.

Bhandari RK, Schinke EN, Haque MM, Sadler-Riggleman I, Skinner MK (2012) SRY induced TCF21 genome-wide targets and cascade of bHLH factors during Sertoli cell differentiation and male sex determination in rats. Biol Reprod 87(6):131PubMed

15.

Wang HC, Peng V, Zhao Y, Sun XH (2012) Enhanced Notch activation is advantageous but not essential for T cell lymphomagenesis in Id1 transgenic mice. PLoS One 7(2):e32944PubMedCentralPubMed

16.

Massari ME, Murre C (2000) Helix–loop–helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol 20(2):429–440PubMedCentralPubMed

17.

Jones S (2004) An overview of the basic helix–loop–helix proteins. Genome Biol 5(6):226PubMedCentralPubMed

18.

Simionato E, Ledent V, Richards G, Thomas-Chollier M, Kerner P, Coornaert D, Degnan BM, Vervoort M (2007) Origin and diversification of the basic helix–loop–helix gene family in metazoans: insights from comparative genomics. BMC Evol Biol 7:33PubMedCentralPubMed

19.

Stevens JD, Roalson EH, Skinner MK (2008) Phylogenetic and expression analysis of the basic helix–loop–helix transcription factor gene family: genomic approach to cellular differentiation. Differentiation 76:1006–1022PubMed

20.

Skinner MK, Rawls A, Wilson-Rawls J, Roalson EH (2010) Basic helix–loop–helix transcription factor gene family phylogenetics and nomenclature. Differentiation 80(1):1–8PubMedCentralPubMed

21.

Savino M, Annibali D, Carucci N, Favuzzi E, Cole MD, Evan GI, Soucek L, Nasi S (2011) The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One 6(7):e22284PubMedCentralPubMed

22.

Ecevit O, Khan MA, Goss DJ (2010) Kinetic analysis of the interaction of b/HLH/Z transcription factors Myc, Max, and Mad with cognate DNA. Biochemistry 49(12):2627–2635PubMedCentralPubMed

23.

Williams SA, Maecker HL, French DM, Liu J, Gregg A, Silverstein LB, Cao TC, Carano RA, Dixit VM (2011) USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell 146(6):918–930PubMed

24.

Fischer A, Gessler M (2007) Delta-Notch–and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 35(14):4583–4596PubMedCentralPubMed

25.

Mimeault M, Batra SK (2013) Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 17(1):30–54PubMedCentralPubMed

26.

Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148(3):399–408PubMedCentralPubMed

27.

Bain G, Gruenwald S, Murre C (1993) E2A and E2-2 are subunits of B-cell-specific E2-box DNA-binding proteins. Mol Cell Biol 13(6):3522–3529PubMedCentralPubMed

28.

Bain G, Robanus Maandag EC, te Riele HP, Feeney AJ, Sheehy A, Schlissel M, Shinton SA, Hardy RR, Murre C (1997) Both E12 and E47 allow commitment to the B cell lineage. Immunity 6(2):145–154PubMed

29.

Kondo M, Cubillo E, Tobiume K, Shirakihara T, Fukuda N, Suzuki H, Shimizu K, Takehara K, Cano A, Saitoh M, Miyazono K (2004) A role for Id in the regulation of TGF-β-induced epithelial–mesenchymal transdifferentiation. Cell Death Differ 11(10):1092–1101PubMed

30.

Slattery C, McMorrow T, Ryan MP (2006) Overexpression of E2A proteins induces epithelial–mesenchymal transition in human renal proximal tubular epithelial cells suggesting a potential role in renal fibrosis. FEBS Lett 580(17):4021–4030PubMed

31.

Cubillo E, Diaz-Lopez A, Cuevas EP, Moreno-Bueno G, Peinado H, Montes A, Santos V, Portillo F, Cano A (2013) E47 and Id1 Interplay in Epithelial-Mesenchymal Transition. PLoS One 8(3):e59948PubMedCentralPubMed

32.

Li Y, Yang J, Luo JH, Dedhar S, Liu Y (2007) Tubular epithelial cell dedifferentiation is driven by the Helix–Loop–Helix transcriptional inhibitor Id1. J Am Soc Nephrol 18(2):449–460PubMed

33.

Sweatt JD (2013) Pitt-Hopkins Syndrome: intellectual disability due to loss of TCF4-regulated gene transcription. Exp Mol Med 45:e21PubMed

34.

Sobrado VR, Moreno-Bueno G, Cubillo E, Holt LJ, Nieto MA, Portillo F, Cano A (2009) The class I bHLH factors E2-2A and E2-2B regulate EMT. J Cell Sci 122:1014–1024PubMed

35.

Peinado H, Marin F, Cubillo E, Stark HJ, Fusenig N, Nieto MA, Cano A (2004) Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. J Cell Sci 117:2827–2839PubMed

36.

Perez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F, Nieto MA, Cano A (2001) A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem 276:27424–27431PubMed

37.

Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927–939PubMed

38.

Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399–1405PubMed

39.

Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X (2005) Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65:5153–5162PubMed

40.

Puisieux A, Valsesia-Wittmann S, Ansieau S (2006) A twist for survival and cancer progression. Br J Cancer 94:13–17PubMedCentralPubMed

41.

Cheng GZ, Zhang W, Wang LH (2008) Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res 68:957–960PubMed

42.

Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, Xu LM, Costanzo C, Cheng JQ, Wang LH (2008) Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 283:14665–14673PubMed

43.

Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP, Xu ZD (2009) Twist1-mediated adriamycin induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15:2657–2665PubMed

44.

Fu J, Qin L, He T, Qin J, Hong J, Wong J, Liao L, Xu J (2011) The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res 21:275–289PubMed

45.

Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C, Puisieux A (2008) Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14(1):79–89PubMed

46.

Okamura H, Yoshida K, Haneji T (2009) Negative regulation of TIMP1 is mediated by transcription factor TWIST1. Int J Oncol 35:181–186PubMed

47.

Perera RJ, Ray A (2007) MicroRNAs in the search for understanding human diseases. BioDrugs 21(2):97–104PubMed

48.

DeSano JT, Xu L (2009) MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J 4:682–692

49.

Mal L, Teruya-Feldstein J, Weinberg RA (2007) Tumor invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163):682–688

50.

Ma L, Weinberg RA (2008) MicroRNAs in malignant progression. Cell Cycle 7(5):570–572PubMed

51.

Liu Y, Sato F, Kawamoto T, Fujimoto K, Morohashi S, Akasaka H, Kondo J, Wu Y, Noshiro M, Kato Y, Kijima H (2010) Anti-apoptotic effect of the basic Helix–Loop–Helix (bHLH) transcription factor DEC2 in human breast cancer cells. Genes Cells 15(4):315–325PubMed

52.

Wu Y, Sato F, Bhawal UK, Kawamoto T, Fujimoto K, Noshiro M, Morohashi S, Kato Y, Kijima H (2011) Basic Helix–Loop–Helix transcription factors DEC1 and DEC2 regulate the paclitaxel-induced apoptotic pathway of MCF-7 human breast cancer cells. Int J Mol Med 4:491–495

53.

Bhawal UK, Sato F, Arakawa Y, Fujimoto K, Kawamoto T, Tanimoto K, Ito Y, Sasahira T, Sakurai T, Kobayashi M, Kashima I, Kijima H, Kuniyasu H, Abiko Y, Kato Y, Sato S (2011) Basic Helix–Loop–Helix transcription factor DEC1 negatively regulates cyclin D1. J Pathol 224(3):420–429PubMed

54.

Wu Y, Sato F, Yamada T, Bhawal UK, Kawamoto T, Fujimoto K, Noshiro M, Seino H, Morohashi S, Hakamada K, Abiko Y, Kato Y, Kijima H (2012) The BHLH transcription factor DEC1 plays an important role in the epithelial-mesenchymal transition of pancreatic cancer. Int J Oncol 41(4):1337–1346PubMed

55.

Yang J, Weinberg RA (2008) Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818–829PubMed

56.

Wiese C, Heisig J, Gessler M (2010) Hey bHLH factors in cardiovascular development. Pediatr Cardiol 31:363–370PubMed

57.

Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L, Sarkar FH (2011) Notch-1 induces epithelial–mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 307(1):26–36PubMedCentralPubMed

58.

Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F (2006) The c-Myc target gene network. Semin Cancer Biol 16(4):253–264PubMed

59.

Liu M, Zhu H, Yang S, Wang Z, Bai J, Xu N (2013) C-Myc suppressed E-cadherin through miR-9 at the post-transcriptional level. Cell Biol Int 37(3):197–202PubMed

60.

Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283(22):14910–14914PubMed

61.

Bai JX, Yan B, Zhao ZN, Xiao X, Qin WW, Zhang R, Jia LT, Meng YL, Jin BQ, Fan DM, Wang T, Yang AG (2013) Tamoxifen represses miR-200 MicroRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-myc in endometrial carcinoma cell lines. Endocrinology 154(2):635–645PubMed

62.

Amatangelo MD, Goodyear S, Varma D, Stearns ME (2012) c-myc expression and MEK1 induced Erk2 nuclear localization are required for TGFbeta induced epithelial-mesenchymal transition and invasion in prostate cancer. Carcinogenesis 33(10):1965–1975PubMed

63.

Shi JW, Liu W, Zhang TT, Wang SC, Lin XL, Li J, Jia JS, Sheng HF, Yao ZF, Zhao WT, Zhao ZL, Xie RY, Yang S, Gao F, Fan QR, Zhang MY, Yue M, Yuan J, Gu WW, Yao KT, Xiao D (2013) The enforced expression of c-Myc in pig fibroblasts triggers mesenchymal-epithelial transition (MET) via F-actin reorganization and RhoA/Rock pathway inactivation. Cell Cycle 12(7):1119–1127PubMed

64.

Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8(12):976–990PubMed

65.

Laurenti E, Wilson A, Trumpp A (2009) Myc’s other life: stem cells and beyond. Curr Opin Cell Biol 21(6):844–854PubMed

66.

Gustafson WC, Weiss WA (2010) Myc proteins as therapeutic targets. Oncogene 29(9):1249–1259PubMedCentralPubMed

67.

Soucek L, Evan GI (2010) The ups and downs of Myc biology. Curr Opin Genet Dev 20(1):91–95PubMedCentralPubMed

68.

Dang CV (2012) MYC on the path to cancer. Cell 149(1):22–35PubMedCentralPubMed

69.

Fong S, Itahana Y, Sumida T, Singh J, Coppe JP, Liu Y, Richards PC, Bennington JL, Lee NM, Debs RJ, Desprez PY (2003) Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci USA. 100(23):13543–13548PubMed

70.

Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J (2005) Genes that mediate breast cancer metastasis to lung. Nature 436(7050):518–524PubMedCentralPubMed

71.

Perk J, Gil-Bazo I, Chin Y, de Candia P, Chen JJ, Zhao Y, Chao S, Cheong W, Ke Y, Al-Ahmadie H, Gerald WL, Brogi E, Benezra R (2006) Reassessment of Id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res 66(22):10870–10877PubMed

72.

Coppe JP, Itahana Y, Moore DH, Bennington JL, Desprez PY (2004) Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res 10(6):2044–2051PubMed

73.

Kondo M, Cubillo E, Tobiume K, Shirakihara T, Fukuda N, Suzuki H, Shimizu K, Takehara K, Cano A, Saitoh M, Miyazono K (2004) A role for Id in the regulation of TGF-beta-induced epithelial-mesenchymal transdifferentiation. Cell Death Differ 11(10):1092–1101PubMed

74.

Kowanetz M, Valcourt U, Bergstrom R, Heldin CH, Moustakas A (2004) Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol 24(10):4241–4254PubMedCentralPubMed

75.

Li Y, Yang J, Luo JH, Dedhar S, Liu Y (2007) Tubular epithelial cell dedifferentiation is driven by the Helix–Loop–Helix transcriptional inhibitor Id1. J Am Soc Nephrol 18(2):449–460PubMed

76.

Ruzinova MB, Benezra R (2003) Id proteins in development, cell cycle and cancer. Trends Cell Biol 13(8):410–418PubMed

77.

Cannito S, Novo E, di Bonzo LV, Busletta C, Colombatto S, Parola M (2010) Epithelial–mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal 12(12):1383–1430PubMed

78.

Chang Q, Jurisica I, Do T, Hedley DW (2011) Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res 71(8):3110–3120PubMed

79.

Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294(5545):1337–1340PubMed

80.

Keith B, Johnson RS, Simon MC (2012) HIF1a and HIF2a: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12(1):9–22

81.

Jiang J, Tang YL, Liang XH (2011) EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther 11(8):714–723PubMed

82.

Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10(3):295–305PubMed

83.

Zhou G, Dada LA, Wu M, Kelly A, Trejo H, Zhou Q, Varga J, Sznajder JI (2009) Hypoxia-induced alveolar epithelial–mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. Am J Physiol Lung Cell Mol Physiol 297(6):L1120–L1130PubMed

84.

Welford SM, Giaccia AJ (2011) Hypoxia and senescence: the impact of oxygenation on tumor suppression. Mol Cancer Res 9(5):538–544PubMedCentralPubMed

85.

Copple BL (2010) Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-beta-dependent mechanisms. Liver Int 30(5):669–682PubMedCentralPubMed

86.

Han WQ, Zhu Q, Hu J, Li PL, Zhang F, Li N (2013) Hypoxia-inducible factor prolyl-hydroxylase-2 mediates transforming growth factor beta 1-induced epithelial-mesenchymal transition in renal tubular cells. Biochim Biophys Acta 1833(6):1454–1462PubMed

87.

Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 105(17):6392–6397PubMed

88.

Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440(7088):1222–1226PubMed

89.

Gonzalez-Moreno O, Lecanda J, Green JE, Segura V, Catena R, Serrano D, Calvo A (2010) VEGF elicits epithelial–mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res 316(4):554–567PubMed

90.

Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM, Mercurio AM (2010) ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 17(4):319–332PubMedCentralPubMed

91.

Du R, Sun W, Xia L, Zhao A, Yu Y, Zhao L, Wang H, Huang C, Sun S (2012) Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS One 7(2):e30771PubMedCentralPubMed

92.

Gessler M, Knobeloch KP, Helisch A, Amann K, Schumacher N, Rohde E, Fischer A, Leimeister C (2002) Mouse gridlock: no aortic coarctation or deficiency, but fatal cardiac defects in Hey2 ⁻/⁻ mice. Curr Biol 12:1601–1604PubMed

93.

Sakata Y, Kamei CN, Nakagami H, Bronson R, Liao JK, Chin MT (2002) Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. Proc Natl Acad Sci USA 99:16197–16202PubMed

94.

Fischer A, Steidl C, Wagner TU, Lang E, Jakob PM, Friedl P, Knobeloch KP, Gessler M (2007) Combined loss of Hey1 and HeyL causes congenital heart defects because of impaired epithelial to mesenchymal transition. Circ Res 100:856–863PubMed

95.

Bildsoe Heidi, Loebel David AF, Jones Vanessa J, Hor Angelyn CC, Braithwaite Antony W, Chen You-Tzung, Behringer Richard R, Tama Patrick PL (2013) The mesenchymal architecture of the cranial mesoderm of mouse embryos is disrupted by the loss of Twist1 function. Dev Biol 374(2):295–307PubMed

96.

Vincentz JW, Barnes RM, Rodgers R, Firulli BA, Conway SJ, Firulli AB (2008) An absence of Twist1 results in aberrant cardiac neural crest morphogenesis. Dev Biol 320(1):131–139PubMedCentralPubMed

97.

Braitsch CM, Combs MD, Quaggin SE, Yutzey KE (2012) Pod1/Tcf21 is regulated by retinoic acid signaling and inhibits differentiation of epicardium-derived cells into smooth muscle in the developing heart. Dev Biol 368(2):345–357PubMedCentralPubMed

98.

Acharya A, Baek ST, Huang G, Eskiocak B, Goetsch S, Sung CY, Banfi S, Sauer MF, Olsen GS, Duffield JS, Olson EN, Tallquist MD (2012) The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development 139(12):2139–2149PubMed

99.

Quaggin SE, Schwartz L, Cui S, Igarashi P, Deimling J, Post M, Rossant J (1999) The basic-Helix–Loop–Helix protein Pod1 is critically important for kidney and lung organogenesis. Development 126(24):5771–5783PubMed

100.

Bondue A, Blanpain C (2010) Mesp1: a key regulator of cardiovascular lineage commitment. Circ Res 107(12):1414–1427PubMed

101.

Morimoto M, Kiso M, Sasaki N, Saga Y (2006) Cooperative Mesp activity is required for normal somitogenesis along the anterior-posterior axis. Dev Biol 300(2):687–698PubMed

102.

Lindsley RC, Gill JG, Murphy TL, Langer EM, Cai M, Mashayekhi M, Wang W, Niwa N, Nerbonne JM, Kyba M, Murphy KM (2008) Mesp1 coordinately regulates cardiovascular fate restriction and epithelial-mesenchymal transition in differentiating ESCs. Cell Stem Cell 3(1):55–68PubMedCentralPubMed

103.

Laffin B, Wellberg E, Kwak HI, Burghardt RC, Metz RP, Gustafson T, Schedin P, Porter WW (2008) Loss of singleminded-2 s in the mouse mammary gland induces an epithelial-mesenchymal transition associated with up-regulation of slug and matrix metalloprotease 2. Mol Cell Biol 28(6):1936–1946PubMedCentralPubMed

104.

Marion JF, Yang C, Caqueret A, Boucher F, Michaud JL (2005) Sim1 and Sim2 are required for the correct targeting of mammillary body axons. Development 132(24):5527–5537PubMed

105.

Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y (2011) Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17(9):1101–1108PubMedCentralPubMed

106.

Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J (2012) Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22(6):725–736PubMedCentralPubMed

107.

Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED (2006) Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66(23):11271–11278PubMed

108.

Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J (2009) miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 4(9):e7181PubMedCentralPubMed

109.

Ocaña OH, Córcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA (2012) Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22(6):709–724PubMed

110.

Lu S, Nie J, Luan Q, Feng Q, Xiao Q, Chang Z, Shan C, Hess D, Hemmings BA, Yang Z (2011) Phosphorylation of the Twist1-family basic Helix–Loop–Helix transcription factors is involved in pathological cardiac remodeling. PLoS One 6(4):e19251PubMedCentralPubMed

111.

Xue G, Hemmings BA (2012) Phosphorylation of basic helix–loop–helix transcription factor Twist in development and disease. Biochem Soc Trans 40(1):90–93PubMed

Titel: The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms
verfasst von: Yue Teng
Xu Li
Publikationsdatum: 01.03.2014
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 3/2014
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-013-9621-6

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice

Key architectural changes in tumor-negative lymph nodes from metastatic-free oral cancer patients are valuable prognostic factors

Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies

Modulation of matrix metalloproteinase-9 secretion from tumor-associated macrophage-like cells by proteolytically processed laminin-332 (laminin-5)

Possible involvement of ΔNp63 downregulation in the invasion and metastasis of oral squamous cell carcinoma via induction of a mesenchymal phenotype

Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie